PTC Therapeutics, Inc.: Form 10-K for the period ended Dec 31, 2024
Filed with the SEC on Feb 27, 2025 and accepted by EDGAR at Feb 27, 2025, 16:32 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2024-01-01 to 2024-12-31 | $806.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 12 months2024-01-01 to 2024-12-31 | $534.5m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2024-01-01 to 2024-12-31 | $300.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2024-01-01 to 2024-12-31 | −$302.6m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2024-01-01 to 2024-12-31 | $176.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2024-01-01 to 2024-12-31 | −$363.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2024-01-01 to 2024-12-31 | −$4.73 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2024-01-01 to 2024-12-31 | −$4.73 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2024-01-01 to 2024-12-31 | 76,845,055 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2024-01-01 to 2024-12-31 | −$107.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2024-01-01 to 2024-12-31 | $6.5m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-12-31 | $779.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-12-31 | $1.37bn | us-gaap:AssetsCurrent |
| Total assets | At period end2024-12-31 | $1.71bn | us-gaap:Assets |
| Current liabilities | At period end2024-12-31 | $581.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-12-31 | $2.80bn | us-gaap:Liabilities |
| Long-term debt | At period end2024-12-31 | $285.4m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2024-12-31 | −$1.10bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001070081-25-000012. Last ingested by Listed: Oct 29, 2026, 18:45 ET. Listed shows no prices and gives no investment advice.